- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00308282
A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis
Phase II Study of Safety and Efficacy of Intravenous LY2127399 in Patients With Rheumatoid Arthritis Treated With Methotrexate
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
-
Bacau, Румыния, 600114
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Baia Mare, Румыния, 430031
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Braila, Румыния, 810217
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Brasov, Румыния, 500365
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Bucharest, Румыния, 024092
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Cluj-Napoca, Румыния, 400006
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Constanta, Румыния, 900607
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Craiova, Румыния, 200322
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Iasi, Румыния, 707061
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Sf. Gheorghe, Румыния, 520064
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Sibiu, Румыния, 550245
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Targoviste, Румыния, 130083
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Targu-Mures, Румыния, 540136
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Timisoara, Румыния, 300002
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Male or female between the ages of 18 and 75 years
- Have given written informed consent approval
- Women must not be at risk to become pregnant during study participation
- Diagnosis of Rheumatoid Arthritis according to the 1987 revised American Rheumatism Association (ARA) criteria for the classification of RA
- Serum C-reactive protein (CRP) measurement greater than the upper limit of normal (ULN, 0.574 mg/dL), or erythrocyte sedimentation rate (ESR) ≥28 mm/hr
- Current, regular use of Methotrexate, at a stable dose
- Biologic DMARD naïve, and have had an insufficient response (in the opinion of the investigator) to an adequate therapeutic dose of at least 1 oral DMARD
Exclusion Criteria:
- Use of excluded medications (reviewed by study doctor)
- Surgical treatment of a joint with 2 months of study enrollment that is to be assessed in the study
- Are unable to ambulate; that is, confined to bed or wheelchair bound
- Have medical findings which, in the opinion of the study doctor, put participant at an unacceptable risk for participation in the study
- Have had recent or ongoing infection which, in the opinion of the study doctor put participant at an unacceptable risk for participation.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Тройной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: А
|
30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6.
Treatment duration: 6 weeks.
|
Плацебо Компаратор: Б
|
IV (in vein) in weeks 0, 3 and 6.
Treatment duration: 6 weeks.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Percentage of Participants Achieving American College of Rheumatology 20% Response (ACR20) (Effectiveness of LY2127399 in Treating Rheumatoid Arthritis Using the ACR20 Scale)
Временное ограничение: Week 16
|
ACR Responder Index is a Composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA).
ACR20 Responders: had ≥20% improvement from baseline in both tender and swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), visual analog pain scale, and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP).
|
Week 16
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Number of Participants With Treatment Emergent Adverse Events (TEAE) (Safety of Repeat Doses (3) of LY2127399 Through Evaluation of Laboratory Tests, Vital Signs and Electrocardiograms)
Временное ограничение: Baseline through Study Completion (Up to 19 Months)
|
Treatment-emergent adverse events (TEAEs) were defined as those AEs with start date and time equal to or after the start of study medication infusion. In the case of a missing onset time for an AE, an AE with a start date equal to or greater than the dosing date was considered treatment-emergent. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section. All participants who received at least one dose of study drug. Due to dosing errors (a participant received 60 mg LY2127399 in the placebo group), the safety population was adjusted to account for actual treatment received. |
Baseline through Study Completion (Up to 19 Months)
|
Evaluation of the Pharmacokinetics of LY2127399: Clearance
Временное ограничение: 2 hours pre-dose, pre-dose, 1 hour and 4 hour(s) post dose
|
Population estimate of constant clearance as determined by population PK analysis.
A 2-compartment model was used in PK modeling.
Constant clearance is the PK parameter which describes the linear elimination of LY2127399 from serum.
|
2 hours pre-dose, pre-dose, 1 hour and 4 hour(s) post dose
|
Percentage of Participants Achieving ACR 50 and ACR70
Временное ограничение: Baseline through Week 24
|
ACR Responder Index: composite of clinical, laboratory, and functional measures of Rheumatoid Arthritis (RA).
ACR50 and ACR70 Responder: had either a ≥50% or ≥70% improvement from baseline in both tender and swollen joint counts and either a ≥50% or ≥70% improvement in at least 3 of 5 criteria: participant's (Pt's) and physician's global assessment of disease activity, HAQ-DI (measured Pts' perceived degree of difficulty performing daily activities), joint pain, and CRP (respectively).
|
Baseline through Week 24
|
Change From Baseline in the Disease Activity Score 28 Joint Count (DAS28-CRP)
Временное ограничение: Baseline, Week 24
|
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP [milligrams per liter (mg/L)], and participant's global assessment of disease activity using visual analog scale (VAS) (participant global VAS).
DAS28-CRP=0.56*square
root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural
log(CRP+1)+0.014*participant
global VAS+0.96.
Scores ranged from 1.0-9.4,
where lower scores indicated less disease activity and remission is DAS28-CRP <2.6.
A negative change indicated an improvement.
|
Baseline, Week 24
|
European League Against Rheumatism (EULAR28) Response: Percentage of Participants With Combined Good and Moderate Responses
Временное ограничение: Baseline, Week 24
|
EULAR Responder index based on 28 joint counts categorizes clinical response based on improvement since baseline in DAS28-CRP.
DAS28-CRP scores range from 1.0-9.4,
where lower scores indicated less disease activity.
High disease activity: DAS28-CRP >5.1, low disease activity: DAS28-CRP <3.2, and remission: DAS28-CRP <2.6.
Participants are categorized as EULAR responders or non-responders (NR) based on improvement of DAS28-CRP scores from baseline.
EULAR DAS28-CRP responder index defines a good (absolute: <3.2 or >1.2 improvement from baseline), moderate (absolute: 3.2-5.1 or 0.6-1.2
improvement from baseline), or no response (absolute: >5.1 or <0.6 improvement from baseline).
Percentage of participants with DAS28-CRP based EULAR response =(number of participants with specific response) / (number of participants analyzed in the group) * 100.
|
Baseline, Week 24
|
Change From Baseline (CFB) in Serum Immunoglobulins IgG, IgA and IgM
Временное ограничение: Baseline, Week 24
|
Immunoglobulins (Ig), or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses.
Their normal blood levels indicate proper immune status.
A negative change indicates a decrease in Ig levels.
|
Baseline, Week 24
|
Change From Baseline in CD20+ B Cell Number Count
Временное ограничение: Baseline, Week 24
|
CD20+ B-cells are a disease-related peripheral blood biomarker used to assess disease progression of Rheumatoid Arthritis (RA).
A reduction in CD20+ B-cell values may indicate an improvement in RA symptoms.
|
Baseline, Week 24
|
Соавторы и исследователи
Спонсор
Публикации и полезные ссылки
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 11055 (Идентификатор реестра: DAIDS ES Registry Number)
- H9B-MC-BCDF (Другой идентификатор: Eli Lilly and Company)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Сроки обмена IPD
Критерии совместного доступа к IPD
Совместное использование IPD Поддерживающий тип информации
- Протокол исследования
- План статистического анализа (SAP)
- Отчет о клиническом исследовании (CSR)
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования LY2127399
-
Eli Lilly and CompanyПрекращеноРевматоидный артритАргентина, Германия, Индия, Корея, Республика, Соединенные Штаты, Венгрия, Тайвань, Болгария, Франция, Российская Федерация, Испания, Украина, Колумбия, Мексика, Польша, Япония, Хорватия, Греция, Новая Зеландия, Румыния, Южная Африка и более
-
Eli Lilly and CompanyЗавершенныйПочечная недостаточность, хроническаяСоединенные Штаты
-
Eli Lilly and CompanyПрекращено
-
Applied Molecular EvolutionEli Lilly and CompanyЗавершенныйМножественная миеломаСоединенные Штаты
-
Eli Lilly and CompanyПрекращеноРевматоидный артритСоединенные Штаты, Германия, Тайвань, Франция, Япония, Мексика, Польша, Российская Федерация, Испания, Колумбия, Аргентина, Греция, Новая Зеландия, Южная Африка, Австралия, Корея, Республика, Бразилия, Италия, Малайзия
-
Eli Lilly and CompanyЗавершенныйРевматоидный артритАргентина, Индия, Соединенные Штаты, Венгрия, Болгария, Мексика, Украина, Колумбия, Тайвань, Польша, Япония, Корея, Республика, Новая Зеландия, Румыния, Южная Африка, Австралия, Хорватия, Литва, Малайзия, Российская Федерация, Сл... и более
-
Eli Lilly and CompanyЗавершенныйСистемная красная волчанка | Аутоиммунное заболевание | Болезнь соединительной тканиИндия, Соединенные Штаты, Венгрия, Румыния, Испания, Франция, Тайвань, Российская Федерация, Соединенное Королевство, Австралия, Латвия, Мексика, Южная Африка, Канада, Израиль, Бразилия, Сербия, Эквадор, Малайзия, Новая Зеландия, Туни...
-
Eli Lilly and CompanyПрекращеноСистемная красная волчанка | Аутоиммунное заболевание | Болезнь соединительной тканиСоединенные Штаты
-
Eli Lilly and CompanyЗавершенный
-
Eli Lilly and CompanyЗавершенныйРевматоидный артритСоединенные Штаты, Мексика, Венгрия, Индия, Аргентина, Чили, Украина, Австралия, Румыния, Германия, Польша, Словакия